Catalyst Wire Dossier Catalyst Wire Dossier

Induced pluripotent stem cell-derived natural killer cells therapy

· Guangzhou Ruixin Biotechnological Co., LTD
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Induced pluripotent stem cell-derived natural killer cells therapy, covering 2024-11-22 to 2024-11-22. Get the full timeline:

Most recent: Clinical Trial Update: Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia [EARLY_Phase 1]

See pricing